Our research results are regularly published in the world's most prestigious medical journals. Treatment takes place at our institute in Graz.
Background
So far, cell-based therapies (CBT, Cellular Based Therapies, BMAC) no better results than PRP achieve.
The Cell extraction was previously not standardized.
We have completed cell extraction using our published reorientation technique optimized and standardized.
Objective: Evaluation of the reorientation technique.
Background
Until now, cell-based therapies (CBT, BMAC) have not been able to achieve better results than PRP. Cell harvesting was not standardized. We have optimized and standardized cell harvesting using our published reorientation technique.
Objective: Five-year results of BMAC in osteoarthritis.
We were the first to routinely examine the number of stem cells in bone marrow. This allowed us to publish the normal distribution of stem cells in the human body as a function of age and diagnosis.
Result: The cell count does not decrease even in old age. Stem cell therapy can therefore still be performed at an advanced age, and this is indeed a worthwhile indication, since surgery (a prosthesis, which we are also happy to perform) poses a much greater risk as an alternative for this patient group.
We were able to publish the first study with the world's longest follow-up period (4 years) for BMAC therapy (stem cell therapy with mesenchymal stem cells) and included patients with severely worn joints (grade III+IV).
Results: Pain, function, and activity levels improve noticeably during both light and strenuous household tasks and sports. Sleep patterns and swelling are positively affected. Improvements begin in the third month and are significantly noticeable after one year. A further significant improvement occurs in the second year, which then remains consistently good at least until the fourth year; longer-term data have not yet been published.
This article compares various injection therapies for the treatment of knee osteoarthritis (OA), including corticosteroids (CS), hyaluronic acid (HA), platelet-rich plasma (PRP), and bone marrow aspirate concentrate (BMA(C)). Osteoarthritis is a common chronic joint disease that often leads to disability. Cell-based therapies such as BMA(C) show promising results. However, conservative treatments such as physical therapy and weight reduction should always be preferred. CS offer short-term pain relief, while HA and PRP achieve longer-lasting improvements. BMA(C) shows significant long-term improvements starting in the second year. It is emphasized that no therapy can be universally recommended, as treatment must be individually tailored.
We have experience with virtually every bone marrow puncture needle on the market and with every collection set/centrifuge used for this purpose.
Result : Many devices only have a CE certificate for a single indication . The cell count varies by a factor of 10 depending on the sampling technique. Interestingly, few practitioners are aware of this, which may explain the poorer results of some competitors.
The study situation in 2024 with several overviews (meta-analyses and reviews) in several centers worldwide for thousands of children speaks of a recommendation class A (strongest recommendation) and level I evidence (highest possible).
Result: On average, the children's ATEC scores improved by 25%, meaning that severe illnesses became moderate and moderate illnesses became mild. Those with mild illnesses improved to such an extent that, on average, they were considered healthy after treatment. Many children made eye contact, began to participate more in social interactions, and expressed emotions more effectively.
We evaluated global data on hip arthroplasty from all available countries between 2005 and 2022. We analyzed relative (annual growth rates, CAGR) and absolute changes, each broken down by age group (≤64 vs. ≥65 years). Additionally, we examined associations with gross domestic product, healthcare expenditure, and life expectancy. Sensitivity analyses were conducted to test the robustness of the results, particularly for the United States. This is the largest study worldwide with the most comprehensive dataset of all available countries.
Results:
Between 2011 and 2022, the overall utilization of hip arthroplasty increased more slowly than between 2005 and 2011 (CAGR: 1,00% vs. 2,03%). For the first time, growth was concentrated among patients ≤64 years of age (CAGR +3,1%), while utilization among patients ≥65 years of age decreased (CAGR -2,3%). Country-specific differences decreased significantly: the ratio between the highest and lowest rates fell from a factor of 7 (2005) to 3 (2022). The pandemic-related slump in 2020 was recovered by 2022 in most countries, but not among those over 65. Analyses confirmed the robustness of the OECD trends; BRIC countries showed stronger increases, albeit with limited comparability.
In 2015, we reported rapid growth and significant disparities in knee arthroplasty in OECD countries, particularly among patients aged ≤ 64 years, and projected a fourfold increase by 2030. Since then, both clinical practice and external conditions have evolved. This study re-examines trends up to 2022 and expands upon previous analyses.
Results:
From 2011 to 2022, the surgical volume continued to increase (CAGR: +2,33% [2,33; 2,34]; MAD: 37.700 [35.700; 39.600]), but more slowly than in the period from 2005 to 2011 (CAGR: +4,75% [4,73; 4,78]; MAD: 58.100 [55.500; 60.700]). Patients aged 64 years and younger now account for approximately 50% of procedures (CAGR: +4,46% [4,28; 5,81]; MAD: 32.300 [30.700; 33.900]), while growth slowed among older adults (CAGR: +0,61% [0,60; 0,61]; MAD: 5.400 [5.000; 5.700]). A one percentage point increase in the obesity rate was associated with a 1,1% to 1,9% increase in utilization; this association was more pronounced in older cohorts and in lower-income countries. COVID-19 led to a decrease of approximately 22%, or about 406.500 [386.600; 426.300 procedures, followed by a faster recovery in younger adults. Growth remains below our original 2015 forecast.
All scientific journals in the world are sorted according to the number of citations in their respective field (1% = best, 100% = worst journal in that field).
A Top 25% paper is one that has been published in a journal that is among the 25% most cited worldwide, thus having a very high impact factor. Among other requirements, habilitation requires at least two publications in a top journal. Because publications in these journals are highly sought after, the acceptance rate is only around 5%, as the quality of the submitted paper is reviewed anonymously by external reviewers.
publications